Just like atomic physics seventy years ago, when it was realized that chain reaction could lead to medical applications as well as to the creation of atomic weapons, the life sciences have entered a grey zone. “Advances in biotechnology […]” a 2003 CIA document stated, “have the potential to create a much more dangerous biological warfare threat […] Engineered biological agents could be much worse than any disease known to man”. As sociologists of science have noted, contemporary life sciences have (...) dual use potential as they can be used to foster beneficial applications, for instance in health care, or generate harm, either intentionally or not, and possibly on an unprecedented.. (shrink)

In science policy, public controversy around synthetic biology has often been presented as a major risk because it could deter innovation. The following inter-related strategies for avoiding contestation have been observed: There have been attempts to close down debates by alluding to the importance and legitimacy of reliance on scientific evidence as input to regulatory processes. Scientific policy advice has stressed sufficiency of existing regulation, economic risks of additional regulation and/or suggestions for monitoring that are limited in scope. Initiatives for (...) self-governance have narrowed the scope of topics for consideration. Engagement with humanities, social sciences and arts has been co-opted for legitimisation and science communication. Although such agendas are of course not ubiquitous, in this paper, I criticise that instrumentally motivated engagement has been supported not only by the scientific community but also by policy institutions and funding bodies. I argue that it is good that this now seems to fuel controversy in the academic and policy realms. As synthetic biology is not the only technoscientific field to see such dynamics, this is also part of the broader context of debate about the governance of science, especially the concept of “responsible research and innovation” currently promoted in the EU. (shrink)